Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents. - Wikidata - wikimedia - TriplyDB

Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents.

Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents.

http://www.wikidata.org/entity/Q38184580

about

Chemotherapy- and irradiation-induced bone loss in adults with solid tumors Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw.Conservative treatment of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].Side effects of bone-targeted therapies in advanced breast cancer.Chemical and Radiation-Associated Jaw Lesions.Osteonecrosis of the jaw associated with ziv-aflibercept Dental extraction following zoledronate, induces osteonecrosis in rat's jaw.Denosumab-related osteonecrosis of the jaw in a patient with bone metastases of prostate cancer: A case report and literature review.Concept, diagnosis and classification of bisphosphonate-associated osteonecrosis of the jaws. A review of the literature.Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study.Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology.Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures.ONJ (osteonecrosis of jaw) in osteoporosis patients after ibandronate treatment: report of two cases.Osteonecrosis of jaw (ONJ) in prostate cancer patients: report of a monoinstitutional experience.Metachronous sites of osteonecrosis of jaw (ONJ) in all four quadrants of maxilla bones and mandible: a case report.Denosumab-related osteonecrosis of the jaw: A retrospective study.BRONJ in patients with rheumatoid arthritis: a multicenter case series.Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol.Osteonecrosis of the Jaw (ONJ) in Osteoporosis Patients: Report of Delayed Diagnosis of a Multisite Case and Commentary about Risks Coming from a Restricted ONJ Definition.Dramatic osteonecrosis of the jaw associated with oral bisphosphonates, periodontitis, and dental implant removal.Osteonecrosis of the Jaw (ONJ) in Osteoporosis Patients: Report of Delayed Diagnosis of a Multisite Case and Commentary about Risks Coming from a Restricted ONJ Definition.Delayed Diagnosis of Osteonecrosis of the Jaw (ONJ) Associated with Bevacizumab Therapy in Colorectal Cancer Patients: Report of Two Cases.Osteonecrosis of the Jaw Associated with Antiangiogenics in Antiresorptive-Naïve Patient: A Comprehensive Review of the Literature.Osteonecrosis of the Jaws (ONJ) after Bisphosphonate Treatment in Patients with Multiple Myeloma: Decreasing ONJ Incidence after Adoption of Preventive Measures.Osteonecrosis of the jaws in cancer patients with bone metastasis: a preliminary analysis of a single center prevention experience.Bevacizumab - related osteonecrosis of jaw in a rectal cancer patient never treated with bisphosphonates.Microsurgical Reconstruction of the Jaws Using Vascularised Free Flap Technique in Patients with Medication-Related Osteonecrosis: A Systematic Review.Bisphosphonate related osteonecrosis of the jaws: case report in patient with multiple myeloma.Could the Combined Administration of Bone Antiresorptive Drug, Taxanes, and Corticosteroids Worsen Medication Related Osteonecrosis of the Jaws in Cancer Patients?The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention Conservative Surgical Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw with Er,Cr:YSGG Laser and Platelet-Rich Plasma: A Longitudinal Study

P2860

Q28084019-55B9AA3D-9811-494B-B2D0-DC85BA374091 Q30239854-3C85A203-DC08-4D32-846F-714758B0C814 Q33865551-DEEEB40B-F181-482B-9586-A6538A2BBF7F Q34512454-5639446F-2B21-4CE1-8F6E-BDF7A6698AFF Q35066955-6E4107E9-EF78-4EED-B989-A584A864BAA8 Q36604330-41D62E46-FE79-4D0A-8E92-974F72EA8399 Q37525339-2460F24A-9093-43A6-817C-C6EA2AD3AEE9 Q37713115-52C3D929-16A0-4161-B8C2-A60F67053257 Q38660112-36DD80DC-53BC-42CF-A82F-A19E541149F9 Q38716842-C16E5BB7-6C3C-4F1A-9EFE-9234C5F0E374 Q38776007-703FFF29-6AF0-4586-B982-8FD21C97DC58 Q38807483-F0E3EF0F-F8E6-4F72-BFDF-0DBBC5E13614 Q39013177-AD45A2C7-84A7-464A-ABD8-1F384D693F54 Q46007868-E628175D-E65D-40EA-B4BF-4F78FE7C6A66 Q46041564-05651BA4-97BA-4461-8D6F-CFBD6E2A579F Q46413278-F3F1D8DE-1863-4814-BBDC-41DD97D5CAB3 Q47251973-FAE110A5-80F6-45AB-AA43-FDE44E82737F Q48829569-A7E9056D-E66B-4A28-9286-8B5A296BBA7F Q50053219-9AC59BBD-DD3B-4672-A703-05D43F2C5CCF Q52643968-D840A7AC-AC33-4525-9142-28D9454113F5 Q53409567-A162EEEE-ECF9-4339-BEA8-691CCF590126 Q55017138-46EB9C69-ABF7-4063-B81E-44B79567FFF8 Q55094789-F8C69C8D-38F8-4EE8-B3FA-FE25C910F333 Q55332559-5E882963-CA83-4EC2-A166-43B3F534A7B6 Q55346257-466A565D-5BF8-49DA-99E6-E2E5F042B56C Q55400309-0A025F25-A81D-4C76-AC60-05404B656C37 Q55407354-EBD83E10-B98A-42E3-AD86-5894CB11AE6B Q55426041-9AEB5F4A-4F7A-4B6B-8A8A-7E0A1A9A47C7 Q55489059-895D19A1-181C-429F-BF8B-9682399B5C85 Q55555000-C3544B0F-72D6-491F-B517-01B6467920EE Q57300255-A069BCD3-62A5-45B5-9512-8FE437B8F7D0 Q58766046-735B4BB1-EDD7-4B8E-B681-EEE972546FE1

P2860

Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents.

http://www.wikidata.org/entity/Q38184580

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Epidemiology, clinical manifes ...... osed to antiresorptive agents.

@en

type

label

Epidemiology, clinical manifes ...... osed to antiresorptive agents.

@en

prefLabel

Epidemiology, clinical manifes ...... osed to antiresorptive agents.

@en

P1433

Q38184580-3506BEAB-0380-4FC5-AAC8-3F13F4F99202

P1476

Q38184580-F54758E7-A3B1-49E2-8195-DA46A1EA734F

P2093

Q38184580-C34E9953-503C-49BA-8699-EF96338A69D3

Q38184580-FC1B7A71-CB64-46AB-93E6-32638DD34D48

P2860

Q38184580-01358663-6284-4A14-9F55-10C2648804A1

Q38184580-04EE6A14-96C0-4EBD-9270-6160F859EB90

Q38184580-0557EAA8-4E88-4456-97C2-BC4779EB2B16

Q38184580-07F9785E-9C75-451B-A37E-E94EB6563BCB

Q38184580-0B904160-6795-4123-AB88-472FD1A3135E

Q38184580-0D236778-DDAB-4060-B6B2-6AA8DE1E9EC6

Q38184580-0FC8ABB2-8464-4F04-9D84-C615521E019C

Q38184580-11180052-AB27-448D-B08D-1D00210348C3

Q38184580-11B055CE-1DA9-4053-89BF-8B383DF3F439

Q38184580-12122D2F-8A24-4136-866C-05289E48C3B9

P304

Q38184580-9138D916-A478-4D6B-B253-9526F1F26F72

P31

Q38184580-86DF95C7-9DB6-4B02-BADE-493DC118D1A5

P356

Q38184580-FDD88227-9358-43A7-9515-385D67CD5A2D

P407

Q38184580-0A75B86D-0E42-4BA4-95DB-D6FD4952C97C

P433

Q38184580-14F41A1B-6473-4E9D-9AA8-53F34C1DDC63

P478

Q38184580-970C46DE-1446-4D30-8F67-B5B42B6934D6

P50

Q38184580-218CB6C1-995B-4683-84E0-99C50D923364

Q38184580-2D20A948-0841-42D2-8704-6E8D0303D5DD

Q38184580-6A6CA57B-E01D-409B-A8B3-B37EFF6331EA

Q38184580-EDB13934-37A7-4CBB-A99C-DE0ADCEB3B23

P577

Q38184580-EA1F1A4B-0684-4867-BE28-7FCDA2CDD579

P5875

Q38184580-A24DD311-0DFB-4666-9E7E-AAA3AB5F8E1E

P698

Q38184580-F7996B68-23E2-4803-970B-626FA1F7A50C

P356

P1433

Future Oncology

P1476

Epidemiology, clinical manifes ...... osed to antiresorptive agents.

@en

P2093

Stefano Fedele

http://www.w3.org/2001/XMLSchema#string

Vittorio Fusco

http://www.w3.org/2001/XMLSchema#string

P2860

The present and future role of bisphosphonates in the management of patients with breast cancer.

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials

Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment

Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis

Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis?

Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology.

American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma.

Bisphosphonate-related osteonecrosis of the jaw: is pH the missing part in the pathogenesis puzzle?

The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data.

P304

257-275

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.13.211

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppina Campisi

Alberto Bedogni

P577

2014-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260064245

http://www.w3.org/2001/XMLSchema#string

P698

24490612

http://www.w3.org/2001/XMLSchema#string